Undisclosed ADC / Samsung - LARVOL DELTA

Samsung Bioepis has submitted an investigational new drug (IND) application for a phase 1 clinical trial of an antibody-drug conjugate (ADC) drug candidate to the U.S. Food and Drug Administration (FDA) (Chosun Biz) - "The company is aiming to enter a global phase 1 trial next year and to produce interim results."

IND • New P1 trial • Bladder Cancer